Catalyst shareholders will receive $28.00 in cash and 0.6606 shares of SXC stock for each Catalyst share, which implies a purchase price of $81.02 per Catalyst share and a premium of approximately 28% based on the closing stock prices of SXC and Catalyst on April 17, 2012 .
The deal is a response to last month’s $29 billion merger of Express Scripts Holdings Co. (NASDAQ: ESRX) and Medco Health. The combined market cap of SXC and Catalyst is $10 billion, a little more than a third of Express Scripts’ $28.5 billion market cap.
Shares of SXC are up about 9.8% at $88.10, which would be a new 52-week high if it holds. Shares of Catalyst are up almost 33% at $84.50, another 52-week high.
Paul Ausick
Contact [email protected] for any questions or corrections.
Top Gaining Stocks
Top Losing Stocks